In recent years, SOR, an oral multiple kinase inhibitor targeting the vascular endothelial growth factor (VEGF), was a targeted treatment drug for advanced HCC, but there had been a low treatment response in the majority of patients during the clinical trials [17]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.